Search results
Questioning America’s Approach to Transgender Health Care
Clinical and Ethical Considerations in the Treatment of Gender Dysphoric Children and Adolescents: When Doing Less Is Helping More
Consistent with the principle, “First, do no harm,” psychologist David Schwartz, Ph.D. exhorts clinicians to treat children and adolescents with gender dysphoria (GD) using psychotherapy rather than pharmacological and surgical interventions. He asserts, “in the treatment of children and...
Bone Mass in Young Adulthood Following Gonadotropin-Releasing Hormone Analog Treatment and Cross-Sex Hormone Treatment in Adolescents With Gender Dysphoria
SEGM Summary:
This retrospective study looked at bone mineral density (BMD) in 34 young gender dysphoric adults at the average age of 22, who had been given gonadotropin releasing hormone analog (GnRHa) to suppress or delay puberty for 1.3 - 1.5 years, followed by cross-sex hormones for...
Evidence review: gonadotrophin releasing hormone analogues for children and adolescents with gender dysphoria
In 2020, the UK National Institute for Health and Care Excellence (NICE) undertook two systematic evidence reviews of the use of GnRH agonists (also known as "puberty blockers") and cross-sex hormones as treatments for...
A big transgender-rights case heads to America’s Supreme Court
National Academy of Medicine in France Advises Caution in Pediatric Gender Transition
Care of children and adolescents with gender dysphoria: summary
In February 2022, the Swedish National Board of Health and Welfare (NBHW) issued an update to its health care service guidelines...
False Assumptions Behind Youth Gender Transitions
Pediatric gender affirming care is not evidence-based
Over the last two years there has been a surge in research studies and systematic reviews reporting on the use of puberty blockers and cross-sex hormones as treatment for gender-distressed youth. This makes it difficult for the non-specialist to keep on top of the evidence. The psychiatrist...